M
Melike Pekmezci
Researcher at University of California, San Francisco
Publications - 139
Citations - 7092
Melike Pekmezci is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Medicine & Glioma. The author has an hindex of 30, co-authored 116 publications receiving 5048 citations. Previous affiliations of Melike Pekmezci include Loyola University Medical Center & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
The epidemiology of glioma in adults: a "state of the science" review.
Quinn T. Ostrom,Luc Bauchet,Faith G. Davis,Isabelle Deltour,James L. Fisher,Chelsea Eastman Langer,Melike Pekmezci,Judith A. Schwartzbaum,Michelle C. Turner,Kyle M. Walsh,Margaret Wrensch,Jill S. Barnholtz-Sloan +11 more
TL;DR: A “state of the science” review of current research into causes and risk factors for gliomas in adults is provided.
Journal ArticleDOI
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
Jeanette E. Eckel-Passow,Daniel H. Lachance,Annette M. Molinaro,Kyle M. Walsh,Paul A. Decker,Hugues Sicotte,Melike Pekmezci,Terri Rice,Matt L. Kosel,Ivan Smirnov,Gobinda Sarkar,Alissa Caron,Thomas M. Kollmeyer,Corinne Praska,Anisha R. Chada,Chandralekha Halder,Helen M. Hansen,Lucie McCoy,Paige M. Bracci,Roxanne Marshall,Shichun Zheng,Gerald F. Reis,Alexander R. Pico,Brian P. O'Neill,Jan C. Buckner,Caterina Giannini,Jason T. Huse,Arie Perry,Tarik Tihan,Mitchell S. Berger,Susan M. Chang,Michael D. Prados,Joseph L. Wiemels,John K. Wiencke,Margaret Wrensch,Robert B. Jenkins +35 more
TL;DR: The five glioma molecular groups had different ages at onset, overall survival, and associations with germline variants, which implies that they are characterized by distinct mechanisms of pathogenesis.
Journal ArticleDOI
The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer
Robert J.A. Bell,H. Tomas Rube,Alex Kreig,Andrew Mancini,Shaun D. Fouse,Raman P. Nagarajan,Serah Choi,Chibo Hong,Daniel He,Melike Pekmezci,John K. Wiencke,Margaret Wrensch,Susan M. Chang,Kyle M. Walsh,Sua Myong,Jun S. Song,Joseph F. Costello +16 more
TL;DR: Cancer-associated mutations in the promoter of the telomerase gene allow increased activation by transcription factor binding, and GABP thus directly links TERT promoter mutations to aberrant expression in multiple cancers.
Journal ArticleDOI
Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.
Melike Pekmezci,Terri Rice,Annette M. Molinaro,Kyle M. Walsh,Paul A. Decker,Helen M. Hansen,Hugues Sicotte,Thomas M. Kollmeyer,Lucie McCoy,Gobinda Sarkar,Arie Perry,Caterina Giannini,Tarik Tihan,Mitchel S. Berger,Joseph L. Wiemels,Paige M. Bracci,Jeanette E. Eckel-Passow,Daniel H. Lachance,Jennifer Leigh Clarke,Jennie Taylor,Tracy Luks,John K. Wiencke,Robert B. Jenkins,Margaret Wrensch +23 more
TL;DR: Evidence is presented that in certain WHO 2016 diagnostic groups, testing for TERT promoter mutations or ATRX alterations may provide additional useful prognostic information.
Journal ArticleDOI
Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.
Pooja Panwalkar,Jonathan Clark,Vijay Ramaswamy,Debra Hawes,Fusheng Yang,Christopher Dunham,Stephen Yip,Juliette Hukin,Yilun Sun,Matthew J. Schipper,Lukas Chavez,Ashley Margol,Melike Pekmezci,Chan Chung,Adam Banda,Jill Bayliss,Sarah J. Curry,Mariarita Santi,Fausto J. Rodriguez,Matija Snuderl,Matthias A. Karajannis,Amanda Saratsis,Amanda Saratsis,Craig Horbinski,Anne Sophie Carret,Beverly Wilson,Donna L. Johnston,Lucie Lafay-Cousin,Shayna Zelcer,David D. Eisenstat,M. Silva,Katrin Scheinemann,Katrin Scheinemann,Nada Jabado,P. Daniel McNeely,Marcel Kool,Stefan M. Pfister,Stefan M. Pfister,Michael D. Taylor,Cynthia Hawkins,Andrey Korshunov,Alexander R. Judkins,Sriram Venneti +42 more
TL;DR: In conclusion, immunohistochemical evaluation of H3K27me3 global reduction is an economic, easily available and readily adaptable method for defining high-risk EPN_PFA from low-risk posterior fossa EPN-PFB tumors to inform prognosis and to enable the design of future clinical trials.